The Association of Polyunsaturated Fatty Acid δ-5-Desaturase Activity with Risk Factors for Type 2 Diabetes Is Dependent on Plasma ApoB-Lipoproteins in Overweight and Obese Adults.
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
received:
08
03
2018
accepted:
24
08
2018
pubmed:
12
12
2018
medline:
7
11
2019
entrez:
12
12
2018
Statut:
ppublish
Résumé
δ-5 and δ-6 desaturases (D5D and D6D) catalyze the endogenous conversion of n-3 (ω-3) and n-6 (ω-6) polyunsaturated fatty acids (PUFAs). Their activities are negatively and positively associated with type 2 diabetes (T2D), respectively, by unclear mechanisms. Elevated plasma apoB-lipoproteins (measured as plasma apoB), which can be reduced by n-3 PUFA intake, promote T2D risk factors. The aim of this study was to test the hypothesis that the association of D5D and D6D activities with T2D risk factors is dependent on plasma apoB. This is a pooled analysis of 2 populations recruited for 2 different metabolic studies. It is a post hoc analysis of baseline data of these subjects [n = 98; 60% women (postmenopausal); mean ± SD body mass index (in kg/m2): 32.8 ± 4.7; mean ± SD age: 57.6 ± 6.3 y]. Glucose-induced insulin secretion (GIIS) and insulin sensitivity (IS) were measured using Botnia clamps. Plasma clearance of a high-fat meal (600 kcal/m2, 66% fat) and white adipose tissue (WAT) function (storage of 3H-triolein-labeled substrate) were assessed in a subpopulation (n = 47). Desaturase activities were estimated from plasma phospholipid fatty acids. Associations were examined using Pearson and partial correlations. While both desaturase activities were positively associated with percentage of eicosapentaenoic acid, only D5D was negatively associated with plasma apoB (r = -0.30, P = 0.003). Association of D5D activity with second-phase GIIS (r = -0.23, P = 0.029), IS (r = 0.33, P = 0.015, in women) and 6-h area-under-the-curve (AUC6h) of plasma chylomicrons (apoB48, r = -0.47, P = 0.020, in women) was independent of age and adiposity, but was eliminated after adjustment for plasma apoB. D6D activity was associated in the opposite direction with GIIS (r = 0.24, P = 0.049), IS (r = -0.36, P = 0.004) and AUC6h chylomicrons (r = 0.52, P = 0.004), independent of plasma apoB. Both desaturases were associated with plasma interleukin-1-receptor antagonist (D5D: r = -0.45, P < 0.001 in women; D6D: r = -0.33, P = 0.007) and WAT function (trend for D5D: r = 0.30, P = 0.05; D6D: r = 0.39, P = 0.027) independent of any adjustment. Association of D5D activity with IS, lower GIIS, and plasma chylomicron clearance is dependent on plasma apoB in overweight and obese adults.
Sections du résumé
Background
δ-5 and δ-6 desaturases (D5D and D6D) catalyze the endogenous conversion of n-3 (ω-3) and n-6 (ω-6) polyunsaturated fatty acids (PUFAs). Their activities are negatively and positively associated with type 2 diabetes (T2D), respectively, by unclear mechanisms. Elevated plasma apoB-lipoproteins (measured as plasma apoB), which can be reduced by n-3 PUFA intake, promote T2D risk factors.
Objective
The aim of this study was to test the hypothesis that the association of D5D and D6D activities with T2D risk factors is dependent on plasma apoB.
Methods
This is a pooled analysis of 2 populations recruited for 2 different metabolic studies. It is a post hoc analysis of baseline data of these subjects [n = 98; 60% women (postmenopausal); mean ± SD body mass index (in kg/m2): 32.8 ± 4.7; mean ± SD age: 57.6 ± 6.3 y]. Glucose-induced insulin secretion (GIIS) and insulin sensitivity (IS) were measured using Botnia clamps. Plasma clearance of a high-fat meal (600 kcal/m2, 66% fat) and white adipose tissue (WAT) function (storage of 3H-triolein-labeled substrate) were assessed in a subpopulation (n = 47). Desaturase activities were estimated from plasma phospholipid fatty acids. Associations were examined using Pearson and partial correlations.
Results
While both desaturase activities were positively associated with percentage of eicosapentaenoic acid, only D5D was negatively associated with plasma apoB (r = -0.30, P = 0.003). Association of D5D activity with second-phase GIIS (r = -0.23, P = 0.029), IS (r = 0.33, P = 0.015, in women) and 6-h area-under-the-curve (AUC6h) of plasma chylomicrons (apoB48, r = -0.47, P = 0.020, in women) was independent of age and adiposity, but was eliminated after adjustment for plasma apoB. D6D activity was associated in the opposite direction with GIIS (r = 0.24, P = 0.049), IS (r = -0.36, P = 0.004) and AUC6h chylomicrons (r = 0.52, P = 0.004), independent of plasma apoB. Both desaturases were associated with plasma interleukin-1-receptor antagonist (D5D: r = -0.45, P < 0.001 in women; D6D: r = -0.33, P = 0.007) and WAT function (trend for D5D: r = 0.30, P = 0.05; D6D: r = 0.39, P = 0.027) independent of any adjustment.
Conclusions
Association of D5D activity with IS, lower GIIS, and plasma chylomicron clearance is dependent on plasma apoB in overweight and obese adults.
Identifiants
pubmed: 30535058
pii: S0022-3166(22)16438-2
doi: 10.1093/jn/nxy238
pmc: PMC6351138
doi:
Substances chimiques
Apolipoproteins B
0
Delta-5 Fatty Acid Desaturase
0
Fatty Acid Desaturases
EC 1.14.19.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-67Subventions
Organisme : CIHR
ID : MOP#93581
Pays : Canada
Organisme : CIHR
ID : 123409
Pays : Canada
Références
J Nutr Sci Vitaminol (Tokyo). 2009;55(5):400-6
pubmed: 19926925
Adv Exp Med Biol. 2014;824:61-81
pubmed: 25038994
Clin Chem. 2010 Apr;56(4):666-70
pubmed: 20110448
Am J Clin Nutr. 2017 Jun;105(6):1544-1551
pubmed: 28424190
Proc Nutr Soc. 2007 May;66(2):237-59
pubmed: 17466105
Ann Nutr Metab. 2014;65(4):310-6
pubmed: 25402168
Sci Rep. 2017 Apr 24;7:46658
pubmed: 28436449
Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E150-9
pubmed: 15191884
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Stat Med. 2002 Oct 15;21(19):2917-30
pubmed: 12325108
Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H813-23
pubmed: 21685264
Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):218-231
pubmed: 29074585
Am J Clin Nutr. 2015 Jul;102(1):155-64
pubmed: 25971719
Diabetes Metab. 2007 Sep;33(4):261-8
pubmed: 17499540
J Hum Nutr Diet. 2015 Dec;28(6):646-58
pubmed: 25208630
J Lipid Res. 2016 Jan;57(1):56-65
pubmed: 26609056
J Lipid Res. 2016 Jun;57(6):1074-85
pubmed: 27040450
Biochem Biophys Res Commun. 2002 Jul 12;295(2):319-23
pubmed: 12150950
J Lipid Res. 2004 Apr;45(4):657-66
pubmed: 14703506
J Lipid Res. 2002 Jun;43(6):979-85
pubmed: 12032174
Diabetes Care. 2003 May;26(5):1395-401
pubmed: 12716795
Am J Clin Nutr. 2013 Jan;97(1):195-207
pubmed: 23221573
Nat Genet. 2010 Feb;42(2):105-16
pubmed: 20081858
Front Genet. 2017 Feb 21;8:21
pubmed: 28270834
PLoS Genet. 2011 Jul;7(7):e1002193
pubmed: 21829377
Am J Clin Nutr. 2018 Jul 1;108(1):62-76
pubmed: 29917037
Acta Diabetol. 2014 Dec;51(6):941-6
pubmed: 24816996
J Clin Lipidol. 2017 Jan - Feb;11(1):34-45.e2
pubmed: 28391908
Biochem Biophys Res Commun. 2014 Aug 8;450(4):1446-51
pubmed: 25017914
Int J Obes (Lond). 2007 Jul;31(7):1119-25
pubmed: 17299378
Appl Physiol Nutr Metab. 2016 Jul;41(7):791-4
pubmed: 27144909
Nutr Diabetes. 2015 Sep 28;5:e180
pubmed: 26417659
Br J Nutr. 2013 Sep 14;110(5):871-9
pubmed: 23414551
Immunity. 2013 Jun 27;38(6):1154-63
pubmed: 23809162
Lancet Diabetes Endocrinol. 2014 Oct;2(10):810-8
pubmed: 25107467
Mol Biol Rep. 2011 Feb;38(2):731-7
pubmed: 20383747
Clin Chem. 1996 May;42(5):732-7
pubmed: 8653899
Cell Rep. 2015 Nov 3;13(5):981-9
pubmed: 26565911
Obesity (Silver Spring). 2017 Mar;25(3):545-552
pubmed: 28145068
Diabetologia. 2006 Jul;49(7):1637-46
pubmed: 16752182
J Clin Lipidol. 2015 Sep-Oct;9(5):664-75
pubmed: 26350813
Nutr Res Rev. 2016 Dec;29(2):202-233
pubmed: 27821191
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2785-93
pubmed: 22995522
J Clin Biochem Nutr. 2011 Sep;49(2):131-5
pubmed: 21980230
Diabetes. 2010 May;59(5):1266-75
pubmed: 20185807
Metabolism. 2016 May;65(5):655-666
pubmed: 27085774
J Clin Endocrinol Metab. 2015 Oct;100(10):3760-9
pubmed: 26284759
J Lipid Res. 2013 Feb;54(2):542-51
pubmed: 23160180
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5862-7
pubmed: 18391222
Front Physiol. 2011 Dec 30;2:112
pubmed: 22232606
PLoS One. 2016 Feb 16;11(2):e0147894
pubmed: 26881936
Curr Opin Lipidol. 2012 Feb;23(1):4-10
pubmed: 22123669
Diabetologia. 2006 Apr;49(4):755-65
pubmed: 16463046
J Lipid Res. 2013 May;54(5):1466-76
pubmed: 23417739
FEBS Lett. 2008 Jun 25;582(15):2291-8
pubmed: 18514070
Biochem Cell Biol. 2004 Feb;82(1):170-90
pubmed: 15052336
Annu Rev Immunol. 2009;27:519-50
pubmed: 19302047
FEBS Lett. 2006 May 1;580(10):2421-9
pubmed: 16616923
Lipids Health Dis. 2009 Aug 27;8:37
pubmed: 19712485
PLoS One. 2010 Apr 09;5(4):e10100
pubmed: 20396381